Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound. That's one of the key reasons Eli Lilly hasn't performed as well in recent months. Since many of ...

resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation ... At the time of their decision, in late 2023, the effects of the drug were still conceptual, and Javier ...

the ingredient that fuels its competing weight loss drug Mounjaro/Zepbound. Investors are more cognizant of Eli Lilly’s presence since it hit markets and offered an alternative to Wegovy.

Apple’s iPads have long been the gold standard in the tablet industry ... The latest iPads feature enclosures made from 100% recycled aluminum, offering a premium and environmentally friendly ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this ... and Eli Lilly's Zepbound, the two top-selling ...